Clinical Trials Browser

NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Phase 2 Active not recruiting

18 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Clinical Trials

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

9-ING-41 in Patients With Advanced Cancers

LASER

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

MK-6482-013

MK-6482-003

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy